

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070171 A2(51) International Patent Classification⁷: A61K

(21) International Application Number: PCT/US03/04501

(22) International Filing Date: 14 February 2003 (14.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/358,006 15 February 2002 (15.02.2002) US(71) Applicant: CORNELL RESEARCH FOUNDATION,
INC. [US/US]; 20 Thornwood Drive, Suite 105, Ithaca, NY
14850 (US).(72) Inventors: GOLDMAN, Steven, A.; 7 Hillcrest Court,
South Salem, NY 10590 (US). ROY, Neeta; 1161 York Ave-
nue, Apt. 7G, Sutton Place, New York, NY 10021 (US).
WINDREM, Martha; 190 Riverside Drive, Apt. 6B, New
York, NY 10024 (US).(74) Agents: GOLDMAN, Michael, L. et al.; Nixon Peabody
LLP, Clinton Square, P.O. Box 31051, Rochester, NY
14603-1051 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IL, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).**Published:**— without international search report and to be republished
upon receipt of that report*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS

(57) Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

- 1 -

MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS

This application claims benefit of U.S. Provisional Patent Application

5 Serial No. 60/358,006, filed February 15, 2002.

The subject matter of this application was made with support from the
United States Government under National Institutes of Health Grant No. NINDS
R01NS39559. The United States Government may have certain rights.

10 FIELD OF THE INVENTION

The present invention is directed to the myelination of congenitally
dysmyelinated forebrains using oligodendrocyte progenitor cells and to a method of
treating a subject having a condition mediated by a loss of myelin or a loss of
15 oligodendrocytes. Also disclosed is a method for the identification and separation of
oligodendrocyte progenitor cells from a mixed population containing other
mammalian brain or spinal cord cell types.

20 BACKGROUND OF THE INVENTION

A broad range of diseases, from the inherited leukodystrophies to
vascular leukoencephalopathies to multiple sclerosis, result from myelin injury or
loss. In the pediatric leukodystrophies, in particular, compact myelin either fails to
properly develop, or is injured in the setting of toxic storage abnormalities. Recent
25 studies have focused on the use of transplanted oligodendrocytes or their progenitors
for the treatment of these congenital myelin diseases. Both rodent and human-derived
cell implants have been assessed in a variety of experimental models of congenital
dysmyelination. The myelinogenic potential of implanted brain cells was first noted
in the shiverer mouse (Lachapelle et al., "Transplantation of CNS Fragments Into the
30 Brain of Shiverer Mutant Mice: Extensive Myelination by Implanted
Oligodendrocytes," Dev. Neurosci 6:325-334 (1983)). The shiverer is a mutant
deficient in myelin basic protein (MBP), by virtue of a premature stop codon in the
MBP gene that results in the omission of its last 5 exons (Roach et al., "Chromosomal

Mapping of Mouse Myelin Basic Protein Gene and Structure and Transcription of the Partially Deleted Gene in Shiverer Mutant Mice," Cell 42:149-155 (1985)). Shiverer is an autosomal recessive mutation, and shi/shi homozygotes fail to develop central compact myelin. They die young, typically by 20-22 weeks of age, with ataxia, dyscoordination, spasticity, and seizures. When fetal human brain tissue was implanted into shiverers, evidence of both oligodendrocytic differentiation and local myelination was noted (Lachapelle et al., "Transplantation of Fragments of CNS Into the Brains of Shiverer Mutant Mice: Extensive Myelination by Implanted Oligodendrocytes," Dev. Neurosci 6:326-334 (1983); Gumpel et al., "Transplantation of Human Embryonic Oligodendrocytes Into Shiverer Brain," Ann NY Acad Sci 495:71-85 (1987); and Seilhean et al., "Myelination by Transplanted Human and Mouse Central Nervous System Tissue After Long-Term Cryopreservation," Acta Neuropathol 91:82-88 (1996)). However, these unfractionated implants yielded only patchy remyelination and would have permitted the co-generation of other, potentially undesired phenotypes. Enriched glial progenitor cells were thus assessed for their myelinogenic capacity, and were found able to myelinate shiverer axons (Warrington et al., "Differential Myelinogenic Capacity of Specific Development Stages of the Oligodendrocyte Lineage Upon Transplantation Into Hypomyelinating Hosts," J. Neurosci Res 34:1-13 (1993)), though with low efficiency, likely due to predominantly astrocytic differentiation by the grafted cells. Snyder and colleagues (Yandava et al., "Global Cell Replacement is Feasible via Neural Stem Cell Transplantation: Evidence from the Dysmyelinated Shiverer Mouse Brain," Proc. Natl. Acad. Sci. 96:7029-7034 (1999)) subsequently noted that immortalized multipotential progenitors could also contribute to myelination in shiverers. Duncan and colleagues similarly noted that oligosphere-derived cells raised from the neonatal rodent subventricular zone could engraft another dysmyelinated mutant, the myelin-deficient rat, upon perinatal intraventricular administration (Learish et al., "Intraventricular Transplantation of Oligodendrocyte Progenitors into a Fetal Myelin Mutant Results in Widespread Formation of Myelin," Ann Neurol 46:716-722 (1999)). These studies notwithstanding, the ability of human oligodendrocyte progenitor cell isolates to myelinate dysmyelinated brain has not hitherto been examined.

The present invention is directed to overcoming the deficiencies in the art.

SUMMARY OF THE INVENTION

5

One aspect of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons.

10

Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes.

15

A further aspect of the present invention relates to an *in vitro* method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This method involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. The oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

20

Applicants have developed means by which glial and oligodendrocytic progenitor cells may be isolated from the human brain; this has allowed the use of highly enriched isolates of native human oligodendrocyte progenitor cells (OPC) for cell transplantation studies.

25

In this study, it was investigated whether highly enriched populations of glial progenitor cells directly isolated from the human brain might be used as a substrate for cell-based therapy of congenital dysmyelination. Specifically, it was postulated that human OPCs, derived from the fetal brain during its period of maximum oligoneogenesis, as well as from the adult brain, would be sufficiently migratory and myelinogenic to mediate the widespread myelination of a perinatal host. This showed that oligodendrocyte progenitor cells could indeed be extracted in

30

- 4 -

bulk and isolated via surface antigen-based FACS from both the fetal and adult human forebrain. These cells were capable of widespread and high-efficiency myelination of the shiverer brain after perinatal xenograft. They infiltrated widely throughout the presumptive white matter, ensheathed resident murine axons, and formed antigenically and ultrastructurally compact myelin. After implantation, the cells slowed their mitotic expansion with time, and generated neither undesired phenotypes nor parenchymal aggregates. Both fetal and adult-derived OPCs were competent to remyelinate murine axons, but important differences were noted: whereas fetal OPCs were highly migratory, they myelinated slowly and inefficiently. In contrast, adult-derived OPCs migrated over lesser distances, but they myelinated more rapidly and in higher proportions than their fetal counterparts. Thus, these isolates of human glial progenitor cells may provide effective cellular substrates for remyelinating the congenitally dys- or hypomyelinated brain. In practical terms, the choice of stage-defined cell type may be dictated by both the availability of donor material, and by the specific biology of the disease target, since both fetal and adult OPCs proved competent to effect structural remyelination.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-D show fluorescence-activated sorting of fetal human oligodendrocyte progenitor cells. This shows the result of dual-color FACS of a 23 week human fetal ventricular zone dissociate, after concurrent immunostaining for both A2B5 and PSA-NCAM. The FACS plot on the left (Figure 1A) illustrates a matched but unstained 23 week dissociate. On the right, Figure 1B shows the same VZ dissociate, sorted after dual immunolabeling for A2B5 (FL1, y axis) and PSA-NCAM (FL2, x axis). Figures 1C-D show A2B5-sorted cells expressed the oligodendrocytic sulfatide antigen recognized by monoclonal antibody O4. The A2B5⁺/PSA-NCAM⁺ fraction in R1R3, comprising 16.5% of the dissociate, corresponded to glial progenitor cells. Although these were able to generate both astrocytes and oligodendrocytes, they were preferentially oligoneogenic when derived at this gestational age, and were thus designated as oligodendrocyte progenitor cells (OPCs). In contrast, the R1R5 fraction, defined by the antigenic phenotype A2B5⁻

/PSA-NCAM⁺, generated largely neurons *in vitro*, and was therefore defined as a neuronal progenitor pool.

Figures 2A-E show fetal human OPCs migrate rapidly to infiltrate the forebrain. This composite shows the distribution of transplanted human cells 4 weeks after perinatal implantation into shiverer recipients. The human cells were localized by anti-human nuclear antigen (ANA) immunostaining; low-power fluorescence images were then collected at representative anteroposterior levels and schematized. The engrafted cells have dispersed widely throughout the forebrain, although most remain in the subcortical white matter tracts. Figure 2A shows a sagittal schematic identifying the levels sampled. Figures 2B-E show sections corresponding to AP 1.25, 1.0, -1.0, and -2.0, in the coronal plane. Scale bar = 3 mm.

Figures 3A-I show engrafted human OPCs myelinate an extensive region of the forebrain. Figures 3A-B show that extensive myelin basic protein expression by sorted human fetal OPCs, implanted into homozygote shiverer mice as neonates, indicates that large regions of the corpus callosum (Figure 3A and Figure 3B, 2 different mice) have myelinated by 12 weeks (MBP). Figure 3C shows that human OPCs also migrated to and myelinated fibers throughout the dorsoventral extents of the internal capsules, manifesting widespread remyelination of the forebrain after a single perinatal injection. Figure 3D demonstrates that myelin basic protein expression, in an engrafted shiverer corpus callosum 3 months after perinatal xenograft, is associated with human donor cells, identified by human nuclear antigen (hNA). Both the engrafted human cells and their associated myelin were invariably found to lay parallel to callosal axonal tracts. Figures 3E-H show confocal optical sections of implanted shiverer corpus callosum, with human cells (hNA) surrounded by myelin basic protein (MBP). Human cells (*arrows*) are found within meshwork of MBP⁺ fibers (Figure 3E, merged image of optical sections Figures 3F-H, taken 1 μ m apart). Figure 3I demonstrates that OPCs were recruited as oligodendrocytes or astrocytes in a context-dependent manner, such that implanted OPCs typically matured as myelinogenic oligodendrocytes in the presumptive white matter, but as GFAP-defined astrocytes in both white and gray matter. This photo shows the striatocallosal border of a shiverer brain, 3 months after perinatal engraftment with human fetal OPCs (hNA). Donor-derived MBP expression is evident in the corpus

callosum, while donor-derived GFAP⁺ astrocytes predominate on the striatal side. Scale bar = 200 μ m. Scale: Figures 3A-C, 1 mm; Figure 3D, 100 μ m; Figures 3E-H, 20 μ m; Figure 3I, 200 μ m.

Figures 4A-G show axonal ensheathment and myelin compaction by engrafted human progenitor cells. Figure 4A is a confocal micrograph showing a triple-immunostain for MBP, human ANA, and neurofilament protein. In this image, all MBP immunostaining is derived from the sorted human OPCs, whereas the NF⁺ axons are those of the mouse host. *Arrows* identify segments of murine axons ensheathed by human oligodendrocytic MBP. Figure 4B is a 2 μ m deep composite of optical sections, taken through the corpus callosum of a shiverer recipient sacrificed 12 weeks after fetal OPC implantation. Shiverer axons were scored as ensheathed when the index lines intersected an NF⁺ axon abutted on each side by MBP-immunoreactivity. The *asterisk* indicates the field enlarged in Figure 4C. In Figure 4C, at higher magnification, MBP-immunoreactivity can be seen to surround ensheathed axons on both sides. Figure 4D is an electron micrographs of a sagittal section through the corpus callosum of an adult shi/shi homozygote. Shiverer axons typically have a single loose wrapping of myelin that fails to compact, so that major dense lines fail to form. Figures 4E-G are representative micrographs of 16-week old shiverer homozygotes, implanted with human oligodendrocyte progenitor cells shortly after birth. These images show resident shiverer axons with densely compacted myelin sheaths. The *asterisk* indicates the field enlarged in the inset. Inset, Major dense lines are noted between myelin lamellae, providing EM confirmation of myelination by engrafted human OPCs. Scale bar = Figure 4A, 20 μ m; Figure 4B, 40 μ m; Figures 4C-F, 1 μ m.

Figures 5A-C show mitotic activity of engrafted progenitors falls with time. Figures 5A-B show BrdU incorporation by transplanted fetal human OPCs, at 4 (Figure 5A) and 12 weeks (Figure 5B) after xenograft. The shiverer recipients were given intraventricular injections of sorted human OPCs on postnatal day 1, then injected with BrdU (100 μ g/g, i.p.) twice daily for 2 days prior to sacrifice. Mitotic human OPCs were observed as BrdU/hNA⁺ cells (*arrows*). Scale bar = 50 μ m. Figure 5C is a regression of the incidence of mitotically-active donor cells as a function of time after perinatal implant. The fraction of human donor cells that

- 7 -

incorporated BrdU during the 48 hrs preceding sacrifice dropped from $42 \pm 6.1\%$ at 4 weeks, to $8.2 \pm 2.4\%$ at 12 weeks. Regression analysis revealed that the rate of BrdU incorporation declined with time according to the exponential regression: $y = 83.4e^{-0.22x}$, with a correlation coefficient of $r = -0.87$ ($p = 0.012$).

5 Figures 6A-F show fetal and adult OPCs differed substantially in their speed and efficiency of myelinogenesis. Figure 6A shows that adult-derived human OPCs (hNA) achieved dense MBP expression by 4 weeks after xenograft. In contrast, Figure 6B shows fetal OPCs expressed no detectable MBP-IR at 4 weeks, with such expression not noted until 12 wks. Scale = 100 μ m. Figures 4C-D are low and high magnification coronal images of the callosal-fimbrial junction of a shiverer homozygote, showing dense myelination by 12 weeks after perinatal engraftment with adult-derived hOPCs. When assessed individually, almost half of the donor cells in this recipient white matter were found to express MBP. Figure 6E shows that a substantially higher proportion of implanted adult OPCs developed MBP expression
10 then did fetal OPCs, when both were assessed at 12 weeks. Figure 6F shows that fetal donor cells nonetheless engrafted more efficiently and in higher numbers than did identically-implanted adult OPCs. * indicates $p < 0.05$; ** $p < 0.005$, each of Student's t-test (2-tailed). Scale: Figures 6A-B, 100 μ m, Figure 6C, 1 mm; Figure 6D, 30 μ m.

20 **DETAILED DESCRIPTION OF THE INVENTION**

As used herein, the term "isolated" when used in conjunction with a nucleic acid molecule refers to: 1) a nucleic acid molecule which has been separated from an organism in a substantially purified form (i.e. substantially free of other
25 substances originating from that organism), or 2) a nucleic acid molecule having the same nucleotide sequence but not necessarily separated from the organism (i.e. synthesized or recombinantly produced nucleic acid molecules).

One aspect of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with
30 oligodendrocyte progenitor cells under conditions which permit remyelination of the axons.

The remyelination of demyelinated axons can be carried out by:

- (1) transuterine fetal intraventricular injection; (2) intraventricular or intraparenchymal (i.e. brain, brain stem, or spinal cord) injections; (3) intraparenchymal injections into adult and juvenile subjects; or (4) intravascular administration. Such administration involves cell doses ranging from 1×10^5 to 5×10^7 , depending on the extent of desired remyelination.

Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes.

Conditions mediated by a loss of myelin include an ischemic demyelination condition, an inflammatory demyelination condition, a pediatric leukodystrophy, mucopolysaccharidosis, perinatal germinal matrix hemorrhage, cerebral palsy, periventricular leukomalacia, radiation-induced conditions, and subcortical leukoencephalopathy due to various etiologies.

Ischemic demyelination conditions include cortical stroke, Lacunar infarct, post-hypoxic leukoencephalopathy, diabetic leukoencephalopathy, and hypertensive leukoencephalopathy.

Inflammatory demyelination conditions include multiple sclerosis, Schilder's Disease, transverse myelitis, optic neuritis, post-vaccination encephalomyelitis, and post-infectious encephalomyelitis.

Pediatric leukodystrophy conditions include lysosomal storage diseases (e.g., Tay-Sachs Disease), Cavavan's Disease, Pelizaens-Merzbacher Disease, and Crabbe's Globoid body leukodystrophy.

An example of mucopolysaccharidosis is Sly's Disease.

Radiation-induced conditions include radiation-induced leukoencephalopathy and radiation-induced myelitis.

Etiologies causing subcortical leukoencephalopathy include HIV/AIDS, head trauma, and multi-infarct states.

Oligodendrocyte progenitor cells are administered in accordance with this aspect of the present invention in substantially the same manner as described

above with regard to treatment of demyelinated axons with oligodendrocyte progenitor cells.

In one embodiment of the present invention, oligodendrocyte progenitor cells are administered to the subject after administering radiation and before demyelination has occurred. The purpose of radiation administration is to treat primary and metastatic tumors of the central nervous system.

The subject treated with oligodendrocyte progenitor cells in accordance with the present invention is preferably a human and, most preferably, an adult or post-natal human.

A further aspect of the present invention relates to an *in vitro* method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This method involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. The oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

The step of removing neurons and neuronal progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types can be carried out by promoter based cell sorting. This procedure includes providing a mixed population of cell types from the brain and spinal cord which population includes neurons and neuronal progenitor cells as well as oligodendrocyte progenitor cells and selecting a promoter which functions in the neurons and neuronal progenitor cells, but not in the oligodendrocyte progenitor cells. A nucleic acid molecule encoding a marker protein under control of the promoter is introduced into the mixed population of cell types, and the population of neurons or neuronal progenitor cells is allowed to express the marker protein. The cells expressing the marker protein are separated from the mixed population of cells, with the separated cells being the neurons and neuronal progenitor cells. The process of selecting neurons and neuronal progenitor cells from a mixed population of cell types using a promoter that functions in the neurons and neuronal progenitor cells and a nucleic acid encoding a marker protein is described in U.S. Patent No. 6,245,564 to Goldman et. al., which is hereby incorporated by reference in its entirety.

The neurons and neuronal progenitor cells can be separated from a mixed population containing other mammalian brain or spinal cord cell types in accordance with the present invention, as long as a promoter specific for the chosen cell is available. "Specific", as used herein to describe a promoter, means that the promoter functions only in the chosen cell type. A chosen cell type can refer to different types of cells or different stages in the developmental cycle of a progenitor cell. For example, the chosen cell may be committed to a particular adult cell phenotype and the chosen promoter only functions in that progenitor cell; i.e. the promoter does not function in adult cells. Although committed and uncommitted progenitor cells may both be considered progenitor cells, these cells are at different stages of progenitor cell development and can be separated according to the present invention if the chosen promoter is specific to the particular stage of the progenitor cell. Those of ordinary skill in the art can readily determine a cell of interest to select based on the availability of a promoter specific for that cell of interest.

Suitable promoters which are specific for neurons or neuronal progenitor cells include a MAP-1B promoter (Liu and Fischer, Gene 171:307-308 (1996), which is hereby incorporated by reference in its entirety), an NCAM promoter (Holst et al., J Biol Chem 269:22245-22252 (1994), which is hereby incorporated by reference in its entirety), an HES-5 HLH protein promoter (Takebayashi et al., J Biol Chem 270:1342-1349 (1995), which is hereby incorporated by reference in its entirety), an α 1-tubulin promoter (Gloster, A., et al., J Neurosci 14:7319-7330 (1994), which is hereby incorporated by reference in its entirety), an α -internexin promoter (Ching et al., J Biol Chem 266:19459-19468 (1991), which is hereby incorporated by reference in its entirety), and a GAP-43 promoter (Starr et al., Brain Res 638:211-220 (1994), which is hereby incorporated by reference in its entirety).

Having determined the promoter specific for the neurons and neuronal progenitor cells, a nucleic acid molecule encoding a protein marker, preferably a green fluorescent protein, under the control of the promoter is introduced into a plurality of cells to be sorted.

The isolated nucleic acid molecule encoding a green fluorescent protein can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA, including messenger RNA or mRNA), genomic or recombinant, biologically isolated or synthetic. The DNA

molecule can be a cDNA molecule, which is a DNA copy of a messenger RNA (mRNA) encoding the GFP. In one embodiment, the GFP can be from *Aequorea victoria* (U.S. Patent No. 5,491,084 to Prasher et. al., which is hereby incorporated by reference in its entirety). A plasmid designated pGFP10.1 has been deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession No. 75547 on September 1, 1993. This plasmid is commercially available from the ATCC due to the issuance of U.S. Patent No. 5,491,084 on February 13, 1996 in which the plasmid is described. This plasmid comprises a cDNA which encodes a green fluorescent protein (GFP) of *Aequorea victoria* as disclosed in U.S. Patent No. 5,491,084 to Chalfie et al., which is hereby incorporated by reference in its entirety. A mutated form of this GFP (a red-shifted mutant form) designated pRSGFP-C1 is commercially available from Clontech Laboratories, Inc. (Palo Alto, California).

The plasmid designated pT α 1-RSGFP has been deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession No. 98298 on January 21, 1997. This plasmid uses the red shifted GFP (RS-GFP) of Clontech Laboratories, Inc. (Palo Alto, California), and the T α 1 promoter sequence provided by Dr. F. Miller (Montreal Neurological Institute, McGill University, Montreal, Canada). In accordance with the subject invention, the T α 1 promoter can be replaced with another specific promoter, and the RS-GFP gene can be replaced with another form of GFP, by using standard restriction enzymes and ligation procedures.

Mutated forms of GFP that emit more strongly than the native protein, as well as forms of GFP amenable to stable translation in higher vertebrates, are now available and can be used for the same purpose. The plasmid designated pT α 1-GFP ϕ has been deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, with the American Type Culture Collection

(ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession No. 98299 on January 21, 1997. This plasmid uses the humanized GFP (GFP_h) of Zolotukhin and Muzyczka (Levy, J., et al., Nature Biotechnol 14:610-614 (1996), which is hereby incorporated by reference in its entirety), and the Tα1 promoter sequence provided by Dr. F. Miller (Montreal). In accordance with the subject invention, the Tα1 promoter can be replaced with another specific promoter, and the GFP_h gene can be replaced with another form of GFP, by using standard restriction enzymes and ligation procedures. Any nucleic acid molecule encoding a fluorescent form of GFP can be used in accordance with the subject invention.

Standard techniques are then used to place the nucleic acid molecule encoding GFP under the control of the chosen cell specific promoter. Generally, this involves the use of restriction enzymes and ligation.

The resulting construct, which comprises the nucleic acid molecule encoding the GFP under the control of the selected promoter (itself a nucleic acid molecule) (with other suitable regulatory elements if desired), is then introduced into a plurality of cells which are to be sorted. Techniques for introducing the nucleic acid molecules of the construct into the plurality of cells may involve the use of expression vectors which comprise the nucleic acid molecules. These expression vectors (such as plasmids and viruses) can then be used to introduce the nucleic acid molecules into the plurality of cells.

Various methods are known in the art for introducing nucleic acid molecules into host cells. These include: 1) microinjection, in which DNA is injected directly into the nucleus of cells through fine glass needles; 2) dextran incubation, in which DNA is incubated with an inert carbohydrate polymer (dextran) to which a positively charged chemical group (DEAE, for diethylaminoethyl) has been coupled (the DNA sticks to the DEAE-dextran via its negatively charged phosphate groups, large DNA-containing particles stick in turn to the surfaces of cells (which are thought to take them in by a process known as endocytosis), and some of the DNA evades destruction in the cytoplasm of the cell and escapes to the nucleus, where it can be transcribed into RNA like any other gene in the cell); 3) calcium phosphate coprecipitation, in which cells efficiently take in DNA in the form of a precipitate with calcium phosphate; 4) electroporation, in which cells are placed in a solution

containing DNA and subjected to a brief electrical pulse that causes holes to open transiently in their membranes so that DNA enters through the holes directly into the cytoplasm, bypassing the endocytotic vesicles through which they pass in the DEAE-dextran and calcium phosphate procedures (passage through these vesicles may sometimes destroy or damage DNA); 5) liposomal mediated transformation, in which DNA is incorporated into artificial lipid vesicles, liposomes, which fuse with the cell membrane, delivering their contents directly into the cytoplasm; 6) biolistic transformation, in which DNA is absorbed to the surface of gold particles and fired into cells under high pressure using a ballistic device; 7) naked DNA insertion; and 8) viral-mediated transformation, in which nucleic acid molecules are introduced into cells using viral vectors. Since viral growth depends on the ability to get the viral genome into cells, viruses have devised efficient methods for doing so. These viruses include retroviruses, lentivirus, adenovirus, herpesvirus, and adeno-associated virus.

As indicated, some of these methods of transforming a cell require the use of an intermediate plasmid vector. U.S. Patent No. 4,237,224 to Cohen and Boyer, which is hereby incorporated by reference in its entirety, describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and replicated in unicellular cultures including procaryotic organisms and eucaryotic cells grown in tissue culture. The DNA sequences are cloned into the plasmid vector using standard cloning procedures known in the art, as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989), which is hereby incorporated by reference in its entirety.

In accordance with one of the above-described methods, the nucleic acid molecule encoding the GFP is thus introduced into a plurality of cells. The promoter which controls expression of the GFP, however, only functions in the cell of interest. Therefore, the GFP is only expressed in the cell of interest. Since GFP is a fluorescent protein, the cells of interest can therefore be identified from among the plurality of cells by the fluorescence of the GFP.

Any suitable means of detecting the fluorescent cells can be used. The cells may be identified using epifluorescence optics, and can be physically picked up

and brought together by Laser Tweezers (Cell Robotics Inc., Albuquerque, New Mexico). They can be separated in bulk through fluorescence activated cell sorting, a method that effectively separates the fluorescent cells from the non-fluorescent cells.

One embodiment of separating oligodendrocyte progenitor cells from the treated mixed population, in accordance with this aspect of the present invention, is carried out by promoter based cell separation as described above, except that rather than starting with the introduction of a nucleic acid molecule encoding a fluorescent protein under control of the promoter into the entire mixed population containing mammalian brain or spinal cord cell types besides the oligodendrocyte progenitor cells, that nucleic acid molecule is introduced into the treated mixed population. In sorting out oligodendrocyte progenitor cells from the treated mixed population, a promoter specific for oligodendrocyte progenitor cells is utilized. The promoter suitable for carrying out this aspect of the present invention can be a cyclic nucleotide phosphorylase I promoter, a myelin basic protein promoter, a JC virus minimal core promoter, a proteolipid protein promoter, a qk1 promoter (i.e. the promoter for the quaking gene product), and a cyclic nucleotide phosphorylase II promoter.

As an alternative to using promoter-based cell sorting to recover oligodendrocyte progenitor cells from the treated mixed population, an immunoseparation procedure is utilized.

This involves separating cells based on proteinaceous surface markers naturally present on progenitor cells of a specific type. For example, the surface marker A2B5 is an initially expressed early oligodendrocyte marker. See Nunes et al., "Identification and Isolation of Multipotential Neural Progenitor Cells from the Adult Human White Matter," Soc. Neurosci. Abstr., (2001), which is hereby incorporated by reference. Using an antibody specific to that marker oligodendrocyte progenitor cells can be separated from a mixed population of cell types. Such antibodies can be labeled with a fluorescent tag to facilitate separation of cells to which they bind. Alternatively, the antibodies can be attached to paramagnetic beads so that cells which bind to the beads through the attached antibodies can be recovered by a biomagnetic separation process.

A hybridoma producing monoclonal antibodies specific to Gq ganglioside, designated A2B5 has been deposited pursuant to, and in satisfaction of,

the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession No. CRL-01520.

- 5 The enriched population of oligodendrocyte progenitor cells is at least 90% pure, preferably at least 95% pure, and most preferably at least 99% pure. The mixed population of cell types used to carry out this aspect of the present invention are preferably human cells. These cells are desirably adult or post-natal human cells.

- Instead of utilizing the above-described procedure of obtaining
- 10 oligodendrocyte progenitor cells by removing neurons and neuronal progenitor cells from a mixed population of brain and spinal cord cell types, leaving a treated mixed population and then separating the oligodendrocyte progenitor cells from the treated population, the oligodendrocyte progenitor cells can be recovered directly from the mixed population of brain and spinal cord cell types using promoter based cell sorting
- 15 as described in U.S. Patent No. 6,245,564 to Goldman, et. al., and U.S. Patent Application Serial No. 09/282,239 to Goldman et. al., which are hereby incorporated by reference in their entirety. This method is essentially as described above, using a promoter which functions only in oligodendrocyte progenitor cells.

EXAMPLES

Example 1 - Cells

- 5 Cells Tissue from late gestational age human fetuses (21 to 23 weeks) were obtained at abortion. The forebrain ventricular/subventricular zones were rapidly dissected free of the remaining brain parenchyma, and the samples chilled on ice. The minced samples were then dissociated using papain/DNAse as previously described (Keyoung et al., "Specific Identification, Selection and Extraction of Neural Stem
- 10 Cells from the Fetal Human Brain," Nature Biotechnology 19:843-850 (2001), which is hereby incorporated by reference in its entirety), always within 3 hours of extraction. The dissociates were then maintained overnight in minimal culture media of DMEM/F12/N1 with 20 ng/ml FGF.

15 Example 2 - Sorting

- The day after dissociation, the cells were incubated 1:1 with MAB A2B5 supernatant (clone 105; ATCC, Manassas, VA), for 30 minutes, then washed and labeled with microbead-tagged rat anti-mouse IgM (Miltenyi Biotech). All incubations were done at 4°C on a rocker. In some instances, 2-channel
- 20 fluorescence-activated cell sorting was done to define the proportions and phenotypic homogeneity of A2B5 and PSA-NCAM-defined subpopulations, using a FACS Vantage SE/Turbo, according to previously described methods (Keyoung et al., "Specific Identification, Selection and Extraction of Neural Stem Cells from the Fetal Human Brain," Nature Biotechnology 19:843-850 (2001) and Roy et al., "In Vitro
- 25 Neurogenesis by Progenitor Cells Isolated from the Adult Human Hippocampus," Nat Med 6:271-277 (2000), which are hereby incorporated by reference in their entirety). More typically, and for all preparative sorts for transplant purposes, magnetic separation of A2B5⁺ cells (MACS; Miltenyi) was next performed, following the manufacturer's protocol. The bound cells were then eluted and incubated with anti-
- 30 NCAM (Pharmingen) at 1:25 for 30 minutes, and labeled with anti-mouse PE at 1:200. The PSA-NCAM⁺ population was then removed by FACS, leaving a highly

- 17 -

enriched population of A2B5⁺/PSA-NCAM⁺ cells. These were maintained *in vitro* for 1-7 days in base media with 20 ng/ml bFGF, until implantation. See Figure 1.

Example 3 - Transplantation and Tagging

5 Homozygous shiverers were bred in a colony. Within a day of birth, the pups were cryoanesthetized for cell delivery. The donor cells were then implanted using a pulled glass pipette inserted through the skull, into either the corpus callosum, the internal capsule, or the lateral ventricle. The pups were then returned to their mother, and later killed after 4, 8, 12, or 16 weeks. For some experiments, recipient
10 mice were injected for 2 days before sacrifice with BrdU (100 µg/g, as a 1.5 mg/100 µl solution), q12 hrs for 2 consecutive days.

Example 4 - Immunohistochemistry

 The transplanted cells were identified using anti-human nuclei
15 antibody from Chemicon (MAB 1281), and either Rhodamine Red X-conjugated goat anti-mouse (Jackson; cat. 115-295-146) or unconjugated rabbit anti-mouse Fab (Jackson 315-007-003) followed by Rhodamine Red X-goat anti-rabbit (Jackson 111-295-144). See Figure 2. CNP was recognized using Sternberger Monoclonal 91, MBP by either Sternberger MAb 94 or Abcam 7349 (rat); human GFAP was detected
20 using anti-human GFAP (Sternberger MAb 21). See Figure 3 and Figures 4A-C. BrdU was immunolabeled concurrently with phenotypic markers as described (Louissaint et al., "Coordinated Interaction of Angiogenesis and Neurogenesis in the Adult Songbird Brain," Neuron 34:945-960 (2002), which is hereby incorporated by reference in its entirety).

25

Example 5 - Electron Microscopy

 Animals were perfused with 4% paraformaldehyde and 0.25% glutaraldehyde in 6% sucrose phosphate buffer (sucrose-PB), post-fixed in the same solution, then sliced by Vibratome in alternating thick (400 µm) and thin (100 µm)
30 sections. The thin sections were immunostained for MBP, while the thick sections were post-fixed in 2% paraformaldehyde and 2.5% glutaraldehyde in sucrose-PB. Those thick sections adjacent to thin sections exhibiting overt MBP expression were

then processed in 1% osmium-1.5% ferricyanide, 1.5% aqueous uranyl acetate, dehydrated through propylene oxide, then embedded in Epon and stained with lead citrate. See Figures 4D-G.

5 **Example 6 - Oligodendrocyte Progenitors Can Be Sorted From the Fetal Human Ventricular Wall**

Cells dissociated from the late second trimester human ventricular zone of 21-23 weeks gestation were first magnetically sorted to isolate A2B5⁺ cells. These included both oligodendrocyte and neuronal progenitor cells. Since PSA-
10 NCAM is expressed by virtually all immature neurons at this stage of human ventricular zone development, FACS was then used to select out PSA-NCAM⁺ cells from the larger A2B5⁺ cell population. This removal from the A2B5⁺ pool of NCAM-defined neuronal progenitor cells and young neurons yielded a subpopulation of A2B5⁺/PSA-NCAM⁻ cells, that defined our oligodendrocyte progenitor pool. By two-
15 color fluorescence-activated cell sorting (FACS), with high-stringency control thresholds intended to limit the incidence of false positives to <0.1%, it was determined that the A2B5⁺/PSA-NCAM⁻ fraction constituted 15.4 ± 4.8% of the cells in these pooled 21-23 week ventricular vzzone samples (n=5) (Figure 1). The glial restriction and oligodendrocytic bias of these VZ progenitors was verified *in vitro*, as
20 the PSA-NCAM-depleted A2B5⁺ pool generated largely oligodendrocytes – and exclusively glia – under basal culture conditions (Figure 1). Under these same conditions, the PSA-NCAM⁺ fraction of A2B5⁺ cells differentiated predominantly into neurons. Thus, two distinct methods of dual antigen immunosorting, two-color FACS and serial immunomagnetic enrichment of A2B5⁺ cells followed by FACS
25 depletion of PSA-NCAM⁺ cells, each permitted the selective enrichment and high-yield extraction of oligodendrocyte progenitor cells from the 21-23 week fetal human ventricular zone. Since the latter technique – immunomagnetic separation followed by single-color FACS depletion - achieved higher net yields than direct two-color FACS, this serial approach was used for extracting and isolating the engrafted human
30 OPC populations.

Example 7 - Implanted Oligodendrocyte Progenitors Migrated Widely After Xenograft

5 Homozygote shi/shi mice were injected intraventricularly and intracallosally with progenitor cell isolates at P0-1. The animals were divided into subgroups that were sacrificed thereafter at 4 week intervals, at 4, 8, 12, or 16 weeks of age. None of the animals were immunosuppressed; perinatal tolerization was relied on to ensure graft acceptance, as a result of which animals were transplanted on either their day of birth or the day after (P0-1), but not beyond. These injections yielded significant and quantifiable cell engraftment (defined as ≥ 100 cells per
10 coronal section at 3 rostrocaudal levels, sampled $>100 \mu\text{m}$ apart), in 34 of the 44 neonatal mice injected for this study (25 of 33 injected with fetal hOPCs, and 9 of 11 injected with adult-derived OPCs). Although aggregates of cells were often noted in the ventricle at 4 weeks, by 12 weeks most if not all implanted cells had penetrated the callosal and fimbrial walls to invade the callosum, fimbria and capsular white
15 matter (Figure 2).

The OPCs typically migrated rapidly, dispersing throughout the subcortical parenchyma from the frontal white matter of the forceps minor rostrally, to the basis pontis caudally. At 4 weeks, the implanted cells, identified by their expression of human nuclear antigen (hNA), were found dispersed widely throughout
20 the white matter, primarily within the corpus callosum, external capsule, and fimbria of the hippocampus (Figure 2). Many nuclei, especially rostral or caudal to the injection site, appeared elongated in the orientation of the tracts, with the morphology of migrants. In addition, a distinct minority entered gray matter regions, including the septum, striatum, and olfactory bulb, and less so the neocortex. By 8 weeks, human
25 cells extended widely throughout the forebrain, and in lesser numbers to the diencephalon. In 2 of these 8-week animals, cells were noted to enter the brainstem white matter tracts, traveling through the cerebral peduncles as far as the basis pontis. In animals allowed to survive for 12 weeks, cells were noted throughout the forebrain, though still primarily within the white matter tracts. Although human nuclei were
30 found both throughout the forebrain, and scattered about the rostral brainstem, xenograft density was invariably greatest in the fimbrial and callosal sites of cell introduction.

Example 8 - Engrafted Fetal Progenitors Matured to Express Myelin Basic Protein

The next question was whether engrafted fetal-derived progenitors
5 matured as myelinogenic oligodendrocytes *in vivo*. To this end, both implanted and unimplanted control mice were immunostained for oligodendrocytic myelin basic protein (MBP), at 4, 8, and 12 weeks after implantation. Since shiverer mice express only the first exon of the MBP gene (Roach, et al., "Chromosomal Mapping of Mouse Myelin Basic Protein Gene and Structure and Transcription of the Partially Deleted
10 Gene in Shiverer Mutant Mice," Cell 42:149-155 (1985), which is hereby incorporated by reference in its entirety). C-terminal-directed anti-MBP antibodies do not recognize the truncated MBP of shiverer homozygotes. As a result, any MBP immunoreactivity detected in transplanted animals necessarily derives from donor-derived oligodendrocytes. At 4 weeks, no detectable MBP was noted in 10 of 11
15 animals, despite widespread cell dispersion; sparse regions of nascent MBP-immunoreactivity were noted in one mouse. At 8 weeks, patchy foci of MBP expression were noted in 4 of 7 mice, typically within their callosa and hippocampal commissures. By 12 weeks though, widespread MBP expression was noted throughout the forebrain white matter tracts in 5 of 7 mice. MBP expression was
20 particularly abundant in the fimbria posteriorly and corpus callosum anteriorly. Indeed, the corpus callosum typically expressed MBP throughout its mediolateral extent, and along its entire length in the sagittal plane (Figures 3A-C).

The broad distribution of myelinogenesis by engrafted cells resulted in a significant volume of myelin reconstitution in the recipient brains. For instance, in
25 the 12-week brain shown in Figure 3, the region of callosal myelination extended about 4 mm rostrocaudally, the length of the corpus callosum, while expanding as a trigone from a mediolateral width of 1 mm caudally to 4 mm rostrally. Given an average callosal depth of 200 μm , the effective volume of MBP-defined myelin production was 1.4 mm^3 . Importantly, this MBP was associated with human donor
30 cells (Figure 3D). To prove that MBP-IR was exclusively associated with the implanted human donor OPCs, confocal imaging was used to examine the co-localization of MBP-immunoreactivity and human nuclear antigen. Using optical

sectioning with orthogonal reconstruction, it was confirmed that the MBP⁺ cells were of human origin, in that each was associated with a human soma, as defined by anti-human nuclear immunostaining (Figures 3E-H).

5 **Example 9 - Progenitor-Derived Oligodendrocytes Remyelinate Axons**

 The next issue was whether the donor-derived myelin actually ensheathed host shiverer axons. To this end, both confocal imaging and electron microscopy were used to assess axonal ensheathment and myelin compaction, respectively. Confocal analysis was first done on a sample of 3 shiverer brains that
10 were each implanted on P1 with 100,000 sorted fetal human OPCs, and then sacrificed at 12 weeks (Figures 4A-C). Regions of callosal MBP expression were first identified by immunolabeling fixed sections. These foci of dense MBP expression were then assessed by confocal imaging after immunolabeling for both human nuclear antigen and neurofilament protein, so as to tag donor-derived cells and host shiverer
15 axons, respectively. By this means, human progenitors were found to have generated myelinating oligodendrocytes in great numbers. The myelin sheaths of these cells were found to be in direct apposition to, and generally completely surrounded, host axons in their immediate vicinity. Among the recipients scored, $11.9 \pm 1.6\%$ (mean \pm SE) of NF⁺ host callosal axons were found to be surrounded by MBP-
20 immunoreactivity (n=3 mice, with 3 fields scored/animal) (Figures 4A-C). Sampling was biased to regions of maximal callosal MBP expression, so that these numbers do not necessarily reflect the incidence of myelination in all forebrain tracts. Rather, these data simply confirm that a significant fraction of resident murine axons may be ensheathed by human myelin following perinatal engraftment of donor progenitor
25 cells.

 Next, electron microscopy was used to verify that host axons were actually ensheathed by donor-derived oligodendrocytes, and that the latter generated ultrastructurally-compact myelin. Since MBP is required for compacting consecutive layers of myelin together, its expression is required for formation of the major dense
30 line of healthy central myelin. In the MBP-deficient shiverer, myelin is only loosely wrapped around axons, fails to exhibit more than a few wrappings, and lacks a major dense line. It was found that in the shi/shi homozygote recipients of perinatal human

progenitor cell transplants, the transplanted human OPCs indeed not only myelinated, but produced compact myelin with major dense lines (Figures 4D-G). When assessed ultrastructurally at both 12 and 16 weeks after implant, the donor-derived myelin was confirmed to surround and ensheath host shiverer axons (Figures 4D-G).

- 5 This ultrastructural analysis allowed quantification of the proportion of axons myelinated by donor-derived OPCs, as a means of validating the data acquired by confocal analysis. In a sample of MBP⁺ fields (n=50), derived from 2 mice implanted on postnatal day 1 and sacrificed for histology 16 weeks later, an overall average of 7.4% of resident callosal axons were found to have donor-derived myelin sheaths (136 of 1832 scored axons), as defined by the presence of major dense lines. As in the confocal analysis, these data reflect the net efficiency of myelination achieved in callosal regions selected on the basis of their MBP-immunoreactivity, and hence defined up-front as areas of successful engraftment; the results are not intended to reflect an unbiased sample of the recipient white matter. That caveat
- 10 notwithstanding, these findings demonstrate that sorted fetal human OPCs can efficiently differentiate as myelinogenic oligodendrocytes upon perinatal xenograft.
- 15

Example 10 - The Proportion of Mitotically Active Donor OPCs Slowly Declined After Xenograft

- 20 The next issue was whether implanted OPCs continued to divide after engraftment, and if so, for how long. To this end, mice were implanted with fetal hOPCs at birth (n=6), and then injected them with BrdU twice a day for two days prior to their terminal sacrifice, at 4, 8, and 12 weeks of age. Immunostaining for BrdU revealed that an average of $42 \pm 6.1\%$ of engrafted human OPCs, implanted on
- 25 the first postnatal day and defined by their expression of anti-human nuclear antigen (hNA), were still actively dividing at 4 weeks of age (Figure 5). In contrast, by 8 and 12 weeks after implantation, the fraction of mitotic BrdU⁺/hNA⁺ cells among the engrafted OPCs fell to 11.2 ± 1.6 and $8.2 \pm 2.4\%$, respectively. These results suggested that the implanted progenitor cells were initially mitotically active for at
- 30 least the first month after engraftment, but then slowed their mitotic activity thereafter, such that less than 10% of all OPCs and progeny thereof were demonstrably cycling by their third month post-implant (Figures 5A-C). Regression

- 23 -

analysis revealed a strong inverse correlation between the mitotic index of donor-derived cells and the length of time post-engraftment ($r=0.90$; $p<0.05$). Importantly, despite the preserved mitotic competence of the implanted progenitor pool, no histologic evidence of tumor formation, anaplasia, or malignant transformation was noted as long as 3 months after implantation in any of the fetal OPC-implanted mice of this study ($n = 34$; including 9 analyzed at 16 weeks).

Example 11 - Many of the Transplanted Cells Differentiated as Astrocytes

Some transplanted fetal OPCs differentiated as astrocytes, as defined by GFAP, and were noted to do so as early as 4 weeks after implantation. These GFAP⁺ astrocytes were found intermingled with MBP⁺ oligodendrocytes, although they typically extended over a wider area than their oligodendrocytic counterparts, which were typically restricted to white matter. Importantly, the implanted fetal hOPCs rarely differentiated as neurons in the shiverer brain: No heterotopic β III-tubulin or MAP2-defined neurons were noted in implanted shiverer white matter at either 4, 8, or 12 weeks after implantation ($n = 33$ total). Similarly, those cells that migrated to the septum or the striatum did not differentiate as neurons; neither did the occasional migrants that were found to enter the dorsal neocortex from the corpus callosum. Only in 2 mice, in which hNA/ β III-tubulin⁺ neurons were found in the olfactory bulb at 4 weeks, were any human donor-derived neurons noted, likely reflecting the particularly neurogenic environment of the olfactory subependyma and bulb. More typically, those donor OPCs that invaded the gray matter typically developed as astrocytes. As a result, the donor-derived astrocytes and oligodendrocytes were typically found in sharply-demarcated geographic domains that corresponded to gray and white matter, respectively. While donor-derived astrocytes were typically more abundant in host gray matter, they were nonetheless dispersed in both gray and white matter; in contrast, donor-derived oligodendrocytes were excluded from the host gray matter (Figure 3I). This segregation of donor-derived glial phenotypes led to sharply defined domain boundaries for the engrafted cells.

Example 12 - Adult-Derived OPCs Myelinate More Rapidly Than Fetal OPCs

Applicants next asked if fetal OPCs differed from their counterparts derived from the adult human brain, with respect to either their migration competence, myelinogenic capacity, or time courses thereof. To this end, 2 litters of shiverer mice were implanted on P0 with A2B5-sorted adult OPCs (n = 12 mice, of whom 9 exhibited successful donor engraftment). These adult-derived hOPCs were extracted from surgical resections of normal human subcortical white matter, from which A2B5⁺ OPCs were extracted via A2B5-directed immunomagnetic sorting (IMS), and then cultured overnight in minimal media prior to their perinatal xenograft. The implanted mice were allowed to survive for either 4, 8, or 12 weeks, then sacrificed for histology. Their brains were sectioned and stained for MBP, GFAP and anti-human nuclear antigen, as had been their fetal OPC-implanted counterparts.

It was found that fetal and adult-derived human oligodendrocyte progenitor cells differed substantially in their respective time courses and efficacy of myelinogenesis upon xenograft. Adult OPCs myelinated shiverer brain more rapidly than their fetal counterparts, achieving widespread and dense MBP expression by 4 weeks after xenograft. In contrast, substantial MBP expression by fetal OPCs was generally not observed until 12 weeks post-implant (Figures 6A-D).

Example 13 - Adult OPCs Produce Myelinogenic Oligodendrocytes with Higher Efficiency Than Fetal OPCs

Besides maturing more quickly than fetal OPCs, adult OPCs were found to give rise to oligodendrocytes in much higher relative proportions, and with much less astrocytic co-generation, than did fetal-derived OPCs. When assessed at the midline of the recipient corpus callosum, $10.2 \pm 4.4\%$ of fetal hNA-defined OPCs expressed MBP at 12 weeks, while virtually none did so at 4 weeks. In contrast, $39.5 \pm 16.3\%$ of adult OPCs expressed MBP by 4 weeks after xenograft into matched recipients ($p < 0.001$ by Student's 2-tailed t-test) (See Figure 6E). Yet substantially higher numbers of fetal donor cells were found in the host brains, compared to identically-implanted adult OPCs (see Figure 6F). Thus, fetal OPCs engrafted into shiverer recipients as well or better than adult OPCs, but those adult cells that did

engraft were at least four-times more likely to mature as oligodendrocytes and develop myelin than their fetal counterparts.

Moreover while adult OPCs largely remained restricted to the host white matter, within which they generated almost entirely MBP⁺ oligodendrocytes, fetal OPCs migrated into both gray and white matter, generating both astrocytes and oligodendrocytes in a context-dependent manner (Figure 3I). Perhaps as a result of their greater speed and efficiency of oligodendrocytic differentiation, implanted adult OPCs and their derivatives rarely migrated beyond the bounds of the white matter, while fetal OPCs migrated widely, with their astrocytic and undifferentiated derivatives extending throughout both the forebrain gray and white matter.

It has thus been shown that highly enriched isolates of human OPCs, sorted from the highly oligoneogenic late second trimester forebrain, can successfully engraft and myelinate the shiverer mouse brain, a genetic model of perinatal leukodystrophy. Specifically, it was found that human OPCs may be selectively extracted from the late second trimester human ventricular zone in high-yield, using FACS directed at the antigenic phenotype A2B5⁺/PSA-NCAM⁺. When implanted to the neonatal murine forebrain, these cells reliably migrated widely throughout the forebrain, maturing in the developing white matter as both oligodendrocytes and astrocytes, and in the presumptive gray matter as astrocytes. Over a period of 4-12 weeks thereafter, the time course depending upon whether the implanted human OPCs were of fetal or adult origin, the donor-derived oligodendrocytes matured to produce myelin, which led to the widespread myelination of resident axons within the shiverer subcortex. This myelination, verified as such by both confocal and ultrastructural analysis, was geographically extensive, and extended throughout all white matter regions of the telencephalon.

Example 14 - High-Yield Purification of Native Human Forebrain OPCs

Applicants had previously found that FACS based upon GFP expression driven by the early oligodendrocytic CNP2 promoter could be used to isolate oligodendrocyte progenitor cells from the adult human white matter (Roy et al., "Identification, Isolation, and Promoter-Defined Separation of Mitotic Oligodendrocyte Progenitor Cells from the Adult Human Subcortical White Matter,"

- Neurosci 19:9986-9995 (1996), which is hereby incorporated by reference in its entirety). These cells expressed the surface ganglioside recognized by the A2B5 antibody, which could also be used to selectively extract the population from the adult white matter (Windrem et al., "Progenitor Cells Derived from the Adult Human Subcortical White Matter Disperse and Differentiate as Oligodendrocytes Within Demyelinated Regions of the Rat Brain," J. Neurosci. Res. 69:966-975 (2002), which is hereby incorporated by reference in its entirety). However, A2B5 recognizes young neurons as well as oligodendrocytes (Eisenbarth et al., "Monoclonal Antibody to a Plasma Membrane Antigen of Neurons," Proc. Natl. Acad. Sci. 76:4913-17 (1979) and Raff et al., "Two Types of Astrocytes in Cultures of the Developing Rat White Matter: Differences in Morphology, Surface Gangliosides, and Growth Characteristics," J. Neurosci. 3:1289-1300 (1983), which are hereby incorporated by reference in their entirety). Thus, although A2B5-based separation may be effectively used to extract OPCs from the adult white matter, which is largely free of neurons, it is not adequate for doing so from fetal brain, in which A2B5⁺ neurons are abundant. To address this issue, applicants double-sorted against both A2B5 and polysialylated N-CAM (PSA-NCAM), which is ubiquitously expressed by young neurons. By excluding PSA-NCAM⁺ cells from the A2B5-sorted sample, a population of cells that gave rise almost exclusively to glia and principally to oligodendrocytes was isolated. This A2B5⁺/PSA-NCAM⁻ phenotype reliably identified an abundant pool of mitotic oligodendrocyte progenitors in the fetal human brain, which appeared analogous to the adult progenitor pool recognized by P/CNP2:hGFP and A2B5 alone. The combination of this high-yield technique for high-grade enrichment of OPCs, combined with the great abundance of OPCs in the highly oligoneogenic 21-23 weeks human ventricular zone, provided for the first time significant quantities of human oligodendrocyte progenitor cells, isolated in a purity and quality appropriate for therapeutic implantation.

Example 15 - Differential Dispersion During Migration

- In these experiments, highly-enriched pools of human OPCs were implanted into the brains of neonatal shiverer mice to assess their migratory activity, oligodendrocytic maturation, and efficiency of myelinogenesis. It was found that the

sorted OPCs proved highly migratory, and reached most structures of the forebrain within 4-8 weeks of implantation (Figure 2). Yet the dispersal patterns of their two derivative phenotypes, oligodendrocytes and astrocytes, differed considerably in their shiverer hosts. Whereas oligodendrocytes were abundant closer to the injection site, astrocytes dispersed more widely, broadly invading the forebrain gray matter. This may have reflected a selection process, with astroglia migrating more rapidly or aggressively than their oligodendrocytic counterparts. Similarly, the A2B5⁺/PSA-NCAM⁺ defined pool may be heterogeneous, such that lineage-restricted oligodendrocyte progenitors may remain near the site of injection, while less differentiated, more motile progenitors might continue to migrate during early expansion, differentiating preferentially as astrocytes upon the cessation of migration. Alternatively, the preferential migration of astroglia to gray matter parenchymal sites may reflect a geographic restriction against oligodendrocytic infiltration beyond the white matter compartment. It is likely that each of these considerations contributes to the different dispersion patterns noted.

Example 16 - Persistence of Uncommitted Progenitors

At all timepoints sampled, large numbers of nestin⁺/hNA⁺ cells were noted that failed to express either astrocytic or oligodendrocytic antigens, and which instead seemed to remain in the host parenchyma as persistent progenitors. The incidence of these uncommitted nestin⁺/GFAP⁺/MBP⁺ donor cells was clearly higher in the fetal than adult-derived grafts. Nonetheless, while most adult-derived OPCs matured as oligodendrocytes, or less so astrocytes, a large fraction remained nestin⁺/GFAP⁺/MBP⁺ (Figure 4A). Such uncommitted cells may constitute both a blessing and a curse in an engrafted recipient – they likely comprise a source of progenitors that can be further stimulated *in vivo*, whether pharmacologically or in response to demyelinative injury, to give rise to myelinogenic oligodendrocytes. On the other hand, they might also represent a potential source of ectopic neurons upon redirection to a neuronal fate; conceivably, they might also constitute a reservoir of mitotically competent cells for later neoplastic transformation (that being said, applicants have never noted tumor formation in any recipient of human brain-derived progenitor cells). Thus, the persistence in engrafted recipients of uncommitted

progenitors, whose phenotypic fate and potential for later expansion remain unclear, provides a cautionary note that must be considered prior to any use of sorted oligodendrocyte progenitor cells in clinical therapeutics.

5 **Example 17 - Clinical Utility**

The above results suggest that congenital dysmyelination, like adult demyelination (Windrem et al., "Progenitor Cells Derived from the Adult Human Subcortical White Matter Disperse and Differentiate as Oligodendrocytes Within Demyelinated Regions of the Rat Brain," J. Neurosci. Res. 69:966-975 (2002), which
10 is hereby incorporated by reference in its entirety), may be an appropriate target for cell-based therapy, using allografts of directly isolated human CNS progenitor cells. In the present study, the effect of donor engraftment and myelination upon either the disease phenotype or survival of the recipient mice was not assessed. However, since the shiverer CNS is dysmyelinated throughout its CNS, it is likely that broad
15 myelination of the brainstem and spinal cord, as well as of the brain, will be required for significant therapeutic benefit. Such widespread graft-associated myelination may require higher cell doses than those used in this study, delivered at multiple injection sites spanning the neuraxis. In this regard, the concurrent injection of higher cell doses into both the cisterna magna and forebrain ventricles may yield substantially
20 wider donor cell engraftment and myelinogenesis than achievable through forebrain injection alone (Mitome et al., "Towards the Reconstruction of Central Nervous System White Matter Using Precursor Cells," Brain 124:2147-2161 (2001), which is hereby incorporated by reference in its entirety).

Such a strategy of cell-based myelination of a dysmyelinated host
25 might be of special benefit when directed at newborn recipients, given the immunological tolerance to alloantigens introduced to neonatal recipients (Ridge et al., "Neonatal Tolerance Revisited: Turning on Newborn T Cells With Dendritic Cells," Science 271:1723-1726 (1996); Roser, B., "Cellular Mechanisms in Neonatal and Adult Tolerance," Immunol. Rev. 107:179-202 (1989); and Witzke et al.,
30 "Induction of Tolerance to Alloantigen," Rev. Immunogenet. 1:374-386 (1999), which are hereby incorporated by reference in their entirety). None of the animals received immunosuppressive therapy, and there was no evidence of immune rejection

- 29 -

of the engrafted human cells. This was in marked contrast to implantation of human OPCs to the adult rat brain, where immune rejection of implanted cells was a sufficient problem to mandate high-dose sustained immunosuppression using cyclosporin (Windrem et al., "Progenitor Cells Derived from the Adult Human Subcortical White Matter Disperse and Differentiate as Oligodendrocytes Within Demyelinated Regions of the Rat Brain," *J. Neurosci. Res.* 69:966-975 (2002), which is hereby incorporated by reference in its entirety). As such, congenital diseases such as the hereditary leukodystrophies, including Krabbe's, Canavan's and Tay-Sach's among others, as well as perinatal germinal matrix hemorrhages and the cerebral palsies, may all prove viable targets for cell-based therapeutic remyelination.

Example 18 - Distinct Features of Fetal and Adult Progenitors

It was surprising to discover that fetal and adult oligodendrocyte progenitor cells differed fundamentally in their time course and efficiency of myelinogenesis (Figure 6). Adult-derived OPCs were able to mature and myelinate much more quickly, and with higher efficiency and in greater relative proportions, than their analogously isolated fetal counterparts. Whereas fetal OPCs were generally not observed to myelinate until 8 weeks after implant, and to not exhibit substantial myelination before 12 weeks, adult OPCs matured and myelinated quickly – almost invariably by 4 weeks. Besides myelinating much more rapidly than their fetal counterparts, adult OPCs matured as myelinogenic oligodendrocytes with much higher efficiency – that is, in much higher relative proportions, and with much less astrocytic co-generation - than fetal-derived progenitors. As a result of their more efficient, rapid, and robust myelination, adult-derived OPCs might appear to constitute a more immediately useful therapeutic vector than the otherwise analogous, and similarly-derived fetal-derived OPCs. This observation has significant implications with regards to the therapeutic application of these cells, most particularly in regards to the disease targets that one might choose to approach with fetal and adult OPCs. Fetal cells might be appropriate therapeutic vectors for preventing dysmyelination in developing brains otherwise destined for congenital dysmyelination, in which endogenous myelination is both slow and delayed. In contrast, diseases of acquired demyelination, in which extant myelin is lost and

- 30 -

mature axons denuded, may require the rapid maturation and myelination offered by adult-derived progenitors.

Thus, human oligodendrocyte progenitor cells may be isolated from both the fetal and adult human brain, each in a purity and yield that permit engraftment for the purpose of therapeutic remyelination. Fetal and adult-derived phenotypes differ, in that whereas fetal OPCs migrate more extensively, adult OPCs generate myelin more rapidly, and with less adventitious astrocytic production. Thus, the two stage-defined phenotypes may prove suited to quite distinct disease targets and therapeutic strategies. Nonetheless, both fetal and adult-derived purified human OPCs may be used to achieve widespread and efficient myelination of the congenitally dysmyelinated mammalian brain.

Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.

WHAT IS CLAIMED:

1. A method of remyelinating demyelinated axons comprising:
treating the demyelinated axons with oligodendrocyte
5 progenitor cells under conditions which permit remyelination of the axons.
2. The method according to claim 1, wherein said treating is
carried out by transuterine fetal intraventricular injection, intraventricular or
intraparenchymal injections, intraparenchymal injections into adult and juvenile
10 subjects, or intravascular administration.
3. A method of treating a subject having a condition mediated by
a loss of myelin or a loss of oligodendrocytes comprising:
administering to the subject oligodendrocyte progenitor cells
15 under conditions effective to treat the condition mediated by a loss of myelin or a loss
of oligodendrocytes.
4. The method according to claim 3, wherein the method is used
to treat a subject with a condition mediated by a loss of oligodendrocytes.
20
5. The method according to claim 3, wherein the method is used
to treat a subject with a condition mediated by a loss of myelin.
6. The method according to claim 5, wherein the condition is an
25 ischemic demyelination condition.
7. The method according to claim 6, wherein the ischemic
demyelination condition is selected from the group consisting of cortical stroke,
Lacunar infarct, post-hypoxic leukoencephalopathy, diabetic leukoencephalopathy,
30 and hypertensive leukoencephalopathy.

- 32 -

8. The method according to claim 5, wherein the condition is an inflammatory demyelination condition.

5 9. The method according to claim 8, wherein the inflammatory demyelination condition is selected from the group consisting of multiple sclerosis, Schilder's Disease, transverse myelitis, optic neuritis, post-vaccination encephalomyelitis, and post-infectious encephalomyelitis.

10 10. The method according to claim 5, wherein the condition is a pediatric leukodystrophy.

11. The method according to claim 10, wherein the pediatric leukodystrophy condition is selected from the group consisting of a lysosomal storage disease, Cavavan's Disease, Pelizaeus-Merzbacher Disease, and Crabbe's Globoid
15 body leukodystrophy.

12. The method according to claim 10, wherein the pediatric leukodystrophy condition is Tay-Sachs Disease.

20 13. A method according to claim 5, wherein the condition is mucopolysaccharidosis.

14. The method according to claim 13, wherein the condition is Sly's Disease.
25

15. The method according to claim 5, wherein the condition is perinatal germinal matrix hemorrhage, periventricular leukoinalacia, or cerebral palsy.

16. The method according to claim 5, wherein the condition is a
30 radiation-induced condition.

17. The method according to claim 16, wherein the radiation-induced condition is radiation-induced leukoencephalopathy or radiation-induced myelitis.

5 18. The method according to claim 5, wherein the condition is an etiology causing sub-cortical leukoencephalopathy, said etiology being HIV/AIDS, head trauma, or multi-infarct states.

10 19. The method according to claim 3, wherein said treating is carried out after administering radiation to the subject and before demyelination has occurred.

15 20. The method according to claim 3, wherein the subject is a human.

21. The method according to claim 20, wherein the subject is a post-natal human.

20 22. The method according to claim 20, wherein the subject is an adult human.

23. The method according to claim 3, wherein the method is carried out in the brain.

25 24. The method according to claim 3, wherein the method is carried out in the spinal cord.

25 25. An *in vitro* method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types, said method comprising:
30 removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population and

separating the oligodendrocyte progenitor cells from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

26. The method according to claim 25, wherein said separating
- 5 oligodendrocyte progenitor cells comprises:
- selecting a promoter which functions only in oligodendrocyte progenitor cells and not in the other cell types;
- introducing a nucleic acid molecule encoding a fluorescent protein under control of said promoter into all cell types of said treated mixed
- 10 population;
- allowing only the oligodendrocyte progenitor cells, but not the other cell types, within said treated mixed population to express said fluorescent protein;
- identifying cells of said treated mixed population of cell types
- 15 that are fluorescent, which are restricted to oligodendrocyte progenitor cells; and
- separating the fluorescent cells from said treated mixed population to form the enriched population of oligodendrocyte progenitor cells.

27. The method according to claim 26, wherein said introducing
- 20 comprises viral mediated transformation of all cell types of said treated mixed population containing other mammalian brain or spinal cord cell types.

28. The method according to claim 27, wherein said viral mediated transformation comprises adenovirus mediated transformation, retrovirus-mediated
- 25 transduction, lentivirus-mediated transduction, or adeno-associated virus-mediated transduction.

29. The method according to claim 26, wherein said introducing comprises electroporation.
- 30

- 35 -

30. The method according to claim 26, wherein said introducing comprises liposomal mediated transformation of all cell types of said treated mixed population containing other mammalian brain or spinal cord cell types.

5 31. The method according to claim 26, wherein said separating the fluorescent cells comprises fluorescence activated cell sorting.

32. The method according to claim 26, wherein said promoter is selected from the group consisting of a cyclic nucleotide phosphorylase I promoter, a myelin basic protein promoter, a JC virus minimal core promoter, a proteolipid
10 protein promoter, a qk1 promoter, and a cyclic nucleotide phosphorylase II promoter.

33. The method according to claim 25, wherein said separating oligodendrocyte progenitor cells comprises:
15 immunoseparating the oligodendrocyte progenitor cells.

34. The method according to claim 33, wherein said immunoseparating is carried out by removing cells from the treated mixed population having an A2B5 antigen.
20

35. The method according to claim 33, wherein said immunoseparating is carried out with a fluorescently labelled antibody which recognizes an antigen on the oligodendrocyte progenitor cells.

25 36. The method according to claim 35, wherein said separating oligodendrocyte progenitor cells further comprises:
fluorescence activated cell sorting.

37. The method according to claim 25, wherein said removing
30 comprises:
selecting a promoter which functions only in neurons and neuronal progenitor cells;

- 36 -

introducing a nucleic acid molecule encoding a marker protein under control of said promoter into the mixed population;

allowing the neurons and neuronal progenitor cells to express the marker protein; and

5 separating the cells expressing the marker protein from the mixed population of cells, wherein said separated cells are the neurons and neuronal progenitor cells.

38. The method according to claim 37, wherein said introducing
10 comprises viral mediated transduction of the mixed population of cells.

39. The method according to claim 38, wherein said viral mediated transduction comprises adenovirus-mediated transduction, retrovirus-mediated transduction, lentivirus-mediated transduction, or adeno-associated virus-mediated
15 transduction.

40. The method according to claim 37, wherein said introducing comprises electroporation.


41. The method according to claim 37, wherein said introducing
20 comprises biolistic transformation.

42. The method according to claim 37, wherein said introducing comprises liposomal mediated transformation.


25 43. The method according to claim 37, wherein the marker protein is a fluorescent protein and said separating comprises fluorescence activated cell sorting.


30 44. The method according to claim 37, wherein the promoter is a T α 1 tubulin promoter, a MAP-1B promoter, an NCAM promoter, An HES-5 HLH promoter, an α -internexin promoter, or a GAP-43 promoter.

45. The method according to claim 25, wherein the cell type is human.
- 5 46. The method according to claim 45, wherein the human is an adult.
47. The method according to claim 45, wherein the human is post-natal.
- 10 48. The enriched population of oligodendrocyte progenitor cells produced according to the process of claim 25.




Figures 1A-D



**Figures 2A-E**




Figures 3A-I



Figures 4A-G

**c****Figures 5A-C**



Figures 6A-F

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 03/070171 A3(51) International Patent Classification⁷: A01N 63/00, 65/00, C12N 5/00, 5/02

(21) International Application Number: PCT/US03/04501

(22) International Filing Date: 14 February 2003 (14.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/358,006 15 February 2002 (15.02.2002) US

(71) Applicant: CORNELL RESEARCH FOUNDATION, INC. [US/US]; 20 Thornwood Drive, Suite 105, Ithaca, NY 14850 (US).

(72) Inventors: GOLDMAN, Steven, A.; 7 Hillcrest Court, South Salem, NY 10590 (US). ROY, Neeta; 1161 York Avenue, Apt. 7G, Sutton Place, New York, NY 10021 (US). WINDREM, Martha; 190 Riverside Drive, Apt. 6B, New York, NY 10024 (US).

(74) Agents: GOLDMAN, Michael, L. et al.; Nixon Peabody LLP, Clinton Square, P.O. Box 31051, Rochester, NY 14603-1051 (US).

(81) Designated States (national): AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PI, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GI, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
6 November 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS

(57) Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/04501

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01N 63/00, 65/00; C12N 5/00, 5/02
 US CL : 424/93.1, 93.7; 435/325

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.1, 93.7; 435/325;

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BLAKEMORE et al. Extensive oligodendrocyte remyelination following injection of cultured central nervous system cells into demyelinating lesions in adult central nervous system. Developmental Neuroscience. 1988, Vol. 10, pages 1-11, entire document.	1-24
Y	GODFRAIND et al. In vivo analysis of glial cell phenotypes during a viral demyelinating disease in mice. J. Cell Biol. November 1989, Vol. 109, pages 2405-2416, entire document.	1-24
Y	GUMPEL et al. Myelination and remyelination in the central nervous system by transplanted oligodendrocytes using the shiverer model. Developmental Neuroscience. 1989, Vol. 11, pages 132-139, entire document.	1-24
Y	WANG et al. Isolation of neuronal precursors by sorting embryonic forebrain transfected with GFP regulated by the Talphal tubulin promoter. Nature Biotechnology. February 1998, Vol. 16, No. 2, pages 196-201, entire document.	25-47
Y	US 6,245,564 B1 (GOLDMAN et al.) 12 June 2001 (12.06.2001), entire document.	25-47

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 August 2003 (22.08.2003)

Date of mailing of the international search report

12 SEP 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 Facsimile No. (703)305-3230

Authorized officer

Anne-Marie Falk, Ph.D.

Telephone No. (703)308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

PCT/US03/04501

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 2002/0061596 A1 (GOLDMAN et al.) 23 May 2002 (23.05.2002), entire document.	25-47
Y	US 2002/0012903 A1 (GOLDMAN et al.) 31 January 2002 (31.01.2002), entire document.	25-48
Y, P	US 6,497,872 B1 (WEISS et al.) 24 December 2002 (24.12.2002), entire document.	1-24
Y, E	US 2003/0049234 A1 (GOLDMAN et al.) 13 March 2003 (13.03.2003), entire document.	25-47

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/04501

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☒

No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Search Authority has found 3 inventions claimed in the International Application covered by the claims indicated below:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-24, drawn to a method of remyelinating demyelinated axons and a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes.

Group II, claims 25-47, drawn to an *in vitro* method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types.

Group III, claim 48, drawn to an enriched population of oligodendrocyte progenitor cells.

This International Searching Authority considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below: The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is the method of treating a subject, whereas the special technical feature of Group II is the *in vitro* method of separating oligodendrocyte progenitor cells from a mixed population, and the special technical feature of Group III is an enriched population of oligodendrocyte progenitor cells. The methods of the inventions of Groups I and II are patentably distinct because they are drawn to materially different methods that require different starting materials, different modes of operation, and produce different effects. Although the composition of the invention of Group III can be used in the method of Group I, its use is not limited to treating a subject as it can also be used to carry out *in vitro* assays. Although the method of the invention of Group II can be used to produce the enriched population of cells of the invention of Group III, the enriched population of cells can also be produced by other methods.

INTERNATIONAL SEARCH REPORT

PCT/US03/04501

WEST

Dialog (file: medicine)

search terms: oligodendrocyte, progenitor, precursor, remyelinat?, demyelinat?, axon, transplant?, A2B5, promoter, fluorescent

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 August 2003 (28.08.2003)

PCT

(10) International Publication Number
WO 2003/070171 A3

(51) International Patent Classification: **A01N 63/00**,
65/00, C12N 5/00, 5/02

(21) International Application Number:
PCT/US2003/004501

(22) International Filing Date: 14 February 2003 (14.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/358,006 15 February 2002 (15.02.2002) US

(71) Applicant: CORNELL RESEARCH FOUNDATION,
INC. [US/US]; 20 Thornwood Drive, Suite 105, Ithaca, NY
14850 (US).

(72) Inventors: GOLDMAN, Steven, A.; 7 Hillcrest Court,
South Salem, NY 10590 (US). ROY, Neeta; 1161 York Ave-
nue, Apt. 7G, Sutton Place, New York, NY 10021 (US).
WINDREM, Martha; 190 Riverside Drive, Apt. 6B, New
York, NY 10024 (US).

(74) Agents: GOLDMAN, Michael, L. et al.; Nixon Peabody
LLP, Clinton Square, P.O. Box 31051, Rochester, NY
14603-1051 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,
SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
6 November 2003

(48) Date of publication of this corrected version:
12 February 2004

(15) Information about Correction:
see PCT Gazette No. 07/2004 of 12 February 2004, Sec-
tion II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PRO-
GENITOR CELLS

(57) Abstract: One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the de-
myelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect
of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligoden-
drocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated
by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying
and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types.
This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to
produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form
an enriched population of oligodendrocyte progenitor cells.

- 1 -

MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS

This application claims benefit of U.S. Provisional Patent Application
5 Serial No. 60/358,006, filed February 15, 2002.

The subject matter of this application was made with support from the
United States Government under National Institutes of Health Grant No. NINDS
R01NS39559. The United States Government may have certain rights.

10

FIELD OF THE INVENTION

The present invention is directed to the myelination of congenitally
dysmyelinated forebrains using oligodendrocyte progenitor cells and to a method of
treating a subject having a condition mediated by a loss of myelin or a loss of
15 oligodendrocytes. Also disclosed is a method for the identification and separation of
oligodendrocyte progenitor cells from a mixed population containing other
mammalian brain or spinal cord cell types.

20

BACKGROUND OF THE INVENTION

A broad range of diseases, from the inherited leukodystrophies to
vascular leukoencephalopathies to multiple sclerosis, result from myelin injury or
loss. In the pediatric leukodystrophies, in particular, compact myelin either fails to
properly develop, or is injured in the setting of toxic storage abnormalities. Recent
25 studies have focused on the use of transplanted oligodendrocytes or their progenitors
for the treatment of these congenital myelin diseases. Both rodent and human-derived
cell implants have been assessed in a variety of experimental models of congenital
dysmyelination. The myelinogenic potential of implanted brain cells was first noted
in the shiverer mouse (Lachapelle et al., "Transplantation of CNS Fragments Into the
30 Brain of Shiverer Mutant Mice: Extensive Myelination by Implanted
Oligodendrocytes," Dev. Neurosci 6:325-334 (1983)). The shiverer is a mutant
deficient in myelin basic protein (MBP), by virtue of a premature stop codon in the
MBP gene that results in the omission of its last 5 exons (Roach et al., "Chromosomal

- 2 -

Mapping of Mouse Myelin Basic Protein Gene and Structure and Transcription of the Partially Deleted Gene in Shiverer Mutant Mice," Cell 42:149-155 (1985)). Shiverer is an autosomal recessive mutation, and shi/shi homozygotes fail to develop central compact myelin. They die young, typically by 20-22 weeks of age, with ataxia, dyscoordination, spasticity, and seizures. When fetal human brain tissue was implanted into shiverers, evidence of both oligodendrocytic differentiation and local myelination was noted (Lachapelle et al., "Transplantation of Fragments of CNS Into the Brains of Shiverer Mutant Mice: Extensive Myelination by Implanted Oligodendrocytes," Dev. Neurosci 6:326-334 (1983); Gumpel et al., "Transplantation of Human Embryonic Oligodendrocytes Into Shiverer Brain," Ann NY Acad Sci 495:71-85 (1987); and Seilhean et al., "Myelination by Transplanted Human and Mouse Central Nervous System Tissue After Long-Term Cryopreservation," Acta Neuropathol 91:82-88 (1996)). However, these unfractionated implants yielded only patchy remyelination and would have permitted the co-generation of other, potentially undesired phenotypes. Enriched glial progenitor cells were thus assessed for their myelinogenic capacity, and were found able to myelinate shiverer axons (Warrington et al., "Differential Myelinogenic Capacity of Specific Development Stages of the Oligodendrocyte Lineage Upon Transplantation Into Hypomyelinating Hosts," J. Neurosci Res 34:1-13 (1993)), though with low efficiency, likely due to predominantly astrocytic differentiation by the grafted cells. Snyder and colleagues (Yandava et al., "Global Cell Replacement is Feasible via Neural Stem Cell Transplantation: Evidence from the Dysmyelinated Shiverer Mouse Brain," Proc. Natl. Acad. Sci. 96:7029-7034 (1999)) subsequently noted that immortalized multipotential progenitors could also contribute to myelination in shiverers. Duncan and colleagues similarly noted that oligosphere-derived cells raised from the neonatal rodent subventricular zone could engraft another dysmyelinated mutant, the myelin-deficient rat, upon perinatal intraventricular administration (Learish et al., "Intraventricular Transplantation of Oligodendrocyte Progenitors into a Fetal Myelin Mutant Results in Widespread Formation of Myelin," Ann Neurol 46:716-722 (1999)). These studies notwithstanding, the ability of human oligodendrocyte progenitor cell isolates to myelinate dysmyelinated brain has not hitherto been examined.

The present invention is directed to overcoming the deficiencies in the art.

SUMMARY OF THE INVENTION

5

One aspect of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons.

10

Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes.

15

A further aspect of the present invention relates to an *in vitro* method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This method involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. The oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

20

25

Applicants have developed means by which glial and oligodendrocytic progenitor cells may be isolated from the human brain; this has allowed the use of highly enriched isolates of native human oligodendrocyte progenitor cells (OPC) for cell transplantation studies.

30

In this study, it was investigated whether highly enriched populations of glial progenitor cells directly isolated from the human brain might be used as a substrate for cell-based therapy of congenital dysmyelination. Specifically, it was postulated that human OPCs, derived from the fetal brain during its period of maximum oligoneogenesis, as well as from the adult brain, would be sufficiently migratory and myelinogenic to mediate the widespread myelination of a perinatal host. This showed that oligodendrocyte progenitor cells could indeed be extracted in

- 4 -

bulk and isolated via surface antigen-based FACS from both the fetal and adult human forebrain. These cells were capable of widespread and high-efficiency myelination of the shiverer brain after perinatal xenograft. They infiltrated widely throughout the presumptive white matter, ensheathed resident murine axons, and formed antigenically and ultrastructurally compact myelin. After implantation, the cells slowed their mitotic expansion with time, and generated neither undesired phenotypes nor parenchymal aggregates. Both fetal and adult-derived OPCs were competent to remyelinate murine axons, but important differences were noted: whereas fetal OPCs were highly migratory, they myelinated slowly and inefficiently. In contrast, adult-derived OPCs migrated over lesser distances, but they myelinated more rapidly and in higher proportions than their fetal counterparts. Thus, these isolates of human glial progenitor cells may provide effective cellular substrates for remyelinating the congenitally dys- or hypomyelinated brain. In practical terms, the choice of stage-defined cell type may be dictated by both the availability of donor material, and by the specific biology of the disease target, since both fetal and adult OPCs proved competent to effect structural remyelination.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-D show fluorescence-activated sorting of fetal human oligodendrocyte progenitor cells. This shows the result of dual-color FACS of a 23 week human fetal ventricular zone dissociate, after concurrent immunostaining for both A2B5 and PSA-NCAM. The FACS plot on the left (Figure 1A) illustrates a matched but unstained 23 week dissociate. On the right, Figure 1B shows the same VZ dissociate, sorted after dual immunolabeling for A2B5 (FL1, y axis) and PSA-NCAM (FL2, x axis). Figures 1C-D show A2B5-sorted cells expressed the oligodendrocytic sulfatide antigen recognized by monoclonal antibody O4. The A2B5⁺/PSA-NCAM⁺ fraction in R1R3, comprising 16.5% of the dissociate, corresponded to glial progenitor cells. Although these were able to generate both astrocytes and oligodendrocytes, they were preferentially oligoneogenic when derived at this gestational age, and were thus designated as oligodendrocyte progenitor cells (OPCs). In contrast, the R1R5 fraction, defined by the antigenic phenotype A2B5⁻

/PSA-NCAM⁺, generated largely neurons *in vitro*, and was therefore defined as a neuronal progenitor pool.

Figures 2A-E show fetal human OPCs migrate rapidly to infiltrate the forebrain. This composite shows the distribution of transplanted human cells 4 weeks after perinatal implantation into shiverer recipients. The human cells were localized by anti-human nuclear antigen (ANA) immunostaining; low-power fluorescence images were then collected at representative anteroposterior levels and schematized. The engrafted cells have dispersed widely throughout the forebrain, although most remain in the subcortical white matter tracts. Figure 2A shows a sagittal schematic identifying the levels sampled. Figures 2B-E show sections corresponding to AP 1.25, 1.0, -1.0, and -2.0, in the coronal plane. Scale bar = 3 mm.

Figures 3A-I show engrafted human OPCs myelinate an extensive region of the forebrain. Figures 3A-B show that extensive myelin basic protein expression by sorted human fetal OPCs, implanted into homozygote shiverer mice as neonates, indicates that large regions of the corpus callosum (Figure 3A and Figure 3B, 2 different mice) have myelinated by 12 weeks (MBP). Figure 3C shows that human OPCs also migrated to and myelinated fibers throughout the dorsoventral extents of the internal capsules, manifesting widespread remyelination of the forebrain after a single perinatal injection. Figure 3D demonstrates that myelin basic protein expression, in an engrafted shiverer callosum 3 months after perinatal xenograft, is associated with human donor cells, identified by human nuclear antigen (hNA). Both the engrafted human cells and their associated myelin were invariably found to lay parallel to callosal axonal tracts. Figures 3E-H show confocal optical sections of implanted shiverer corpus callosum, with human cells (hNA) surrounded by myelin basic protein (MBP). Human cells (*arrows*) are found within meshwork of MBP⁺ fibers (Figure 3E, merged image of optical sections Figures 3F-H, taken 1 μ m apart). Figure 3I demonstrates that OPCs were recruited as oligodendrocytes or astrocytes in a context-dependent manner, such that implanted OPCs typically matured as myelinogenic oligodendrocytes in the presumptive white matter, but as GFAP-defined astrocytes in both white and gray and white matter. This photo shows the striatocallosal border of a shiverer brain, 3 months after perinatal engraftment with human fetal OPCs (hNA). Donor-derived MBP expression is evident in the corpus

callosum, while donor-derived GFAP⁺ astrocytes predominate on the striatal side. Scale bar = 200 μ m. Scale: Figures 3A-C, 1 mm; Figure 3D, 100 μ m; Figures 3E-H, 20 μ m; Figure 3I, 200 μ m.

Figures 4A-G show axonal ensheathment and myelin compaction by engrafted human progenitor cells. Figure 4A is a confocal micrograph showing a triple-immunostain for MBP, human ANA, and neurofilament protein. In this image, all MBP immunostaining is derived from the sorted human OPCs, whereas the NF⁺ axons are those of the mouse host. *Arrows* identify segments of murine axons ensheathed by human oligodendrocytic MBP. Figure 4B is a 2 μ m deep composite of optical sections, taken through the corpus callosum of a shiverer recipient sacrificed 12 weeks after fetal OPC implantation. Shiverer axons were scored as ensheathed when the index lines intersected an NF⁺ axon abutted on each side by MBP-immunoreactivity. The *asterisk* indicates the field enlarged in Figure 4C. In Figure 4C, at higher magnification, MBP-immunoreactivity can be seen to surround ensheathed axons on both sides. Figure 4D is an electron micrographs of a sagittal section through the corpus callosum of an adult shi/shi homozygote. Shiverer axons typically have a single loose wrapping of myelin that fails to compact, so that major dense lines fail to form. Figures 4E-G are representative micrographs of 16-week old shiverer homozygotes, implanted with human oligodendrocyte progenitor cells shortly after birth. These images show resident shiverer axons with densely compacted myelin sheaths. The *asterisk* indicates the field enlarged in the inset. Inset, Major dense lines are noted between myelin lamellae, providing EM confirmation of myelination by engrafted human OPCs. Scale bar = Figure 4A, 20 μ m; Figure 4B, 40 μ m; Figures 4C-F, 1 μ m.

Figures 5A-C show mitotic activity of engrafted progenitors falls with time. Figures 5A-B show BrdU incorporation by transplanted fetal human OPCs, at 4 (Figure 5A) and 12 weeks (Figure 5B) after xenograft. The shiverer recipients were given intraventricular injections of sorted human OPCs on postnatal day 1, then injected with BrdU (100 μ g/g, i.p.) twice daily for 2 days prior to sacrifice. Mitotic human OPCs were observed as BrdU/hNA⁺ cells (*arrows*). Scale bar = 50 μ m. Figure 5C is a regression of the incidence of mitotically-active donor cells as a function of time after perinatal implant. The fraction of human donor cells that

- 7 -

incorporated BrdU during the 48 hrs preceding sacrifice dropped from $42 \pm 6.1\%$ at 4 weeks, to $8.2 \pm 2.4\%$ at 12 weeks. Regression analysis revealed that the rate of BrdU incorporation declined with time according to the exponential regression: $y = 83.4e^{-0.22x}$, with a correlation coefficient of $r = -0.87$ ($p = 0.012$).

- 5 Figures 6A-F show fetal and adult OPCs differed substantially in their speed and efficiency of myelinogenesis. Figure 6A shows that adult-derived human OPCs (hNA) achieved dense MBP expression by 4 weeks after xenograft. In contrast, Figure 6B shows fetal OPCs expressed no detectable MBP-IR at 4 weeks, with such expression not noted until 12 wks. Scale = 100 μm . Figures 4C-D are low and high
- 10 magnification coronal images of the callosal-fimbrial junction of a shiverer homozygote, showing dense myelination by 12 weeks after perinatal engraftment with adult-derived hOPCs. When assessed individually, almost half of the donor cells in this recipient white matter were found to express MBP. Figure 6E shows that a
- 15 substantially higher proportion of implanted adult OPCs developed MBP expression than did fetal OPCs, when both were assessed at 12 weeks. Figure 6F shows that fetal donor cells nonetheless engrafted more efficiently and in higher numbers than did identically-implanted adult OPCs. * indicates $p < 0.05$; ** $p < 0.005$, each of Student's t-test (2-tailed). Scale: Figures 6A-B, 100 μm , Figure 6C, 1 mm; Figure 6D, 30 μm .

20 DETAILED DESCRIPTION OF THE INVENTION

- As used herein, the term "isolated" when used in conjunction with a nucleic acid molecule refers to: 1) a nucleic acid molecule which has been separated from an organism in a substantially purified form (i.e. substantially free of other
- 25 substances originating from that organism), or 2) a nucleic acid molecule having the same nucleotide sequence but not necessarily separated from the organism (i.e. synthesized or recombinantly produced nucleic acid molecules).

- One aspect of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with
- 30 oligodendrocyte progenitor cells under conditions which permit remyelination of the axons.

The remyelination of demyelinated axons can be carried out by:

- (1) transuterine fetal intraventricular injection; (2) intraventricular or intraparenchymal (i.e. brain, brain stem, or spinal cord) injections; (3) intraparenchymal injections into adult and juvenile subjects; or (4) intravascular administration. Such administration involves cell doses ranging from 1×10^5 to 5×10^7 , depending on the extent of desired remyelination.

- Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes.

- Conditions mediated by a loss of myelin include an ischemic demyelination condition, an inflammatory demyelination condition, a pediatric leukodystrophy, mucopolysaccharidosis, perinatal germinal matrix hemorrhage, cerebral palsy, periventricular leukomalacia, radiation-induced conditions, and subcortical leukoencephalopathy due to various etiologies.

- Ischemic demyelination conditions include cortical stroke, Lacunar infarct, post-hypoxic leukoencephalopathy, diabetic leukoencephalopathy, and hypertensive leukoencephalopathy.

- Inflammatory demyelination conditions include multiple sclerosis, Schilder's Disease, transverse myelitis, optic neuritis, post-vaccination encephalomyelitis, and post-infectious encephalomyelitis.

- Pediatric leukodystrophy conditions include lysosomal storage diseases (e.g., Tay-Sachs Disease), Cavavan's Disease, Pelizaens-Merzbacher Disease, and Crabbe's Globoid body leukodystrophy.

An example of mucopolysaccharidosis is Sly's Disease.

Radiation-induced conditions include radiation-induced leukoencephalopathy and radiation-induced myelitis.

- Etiologies causing subcortical leukoencephalopathy include HIV/AIDS, head trauma, and multi-infarct states.

Oligodendrocyte progenitor cells are administered in accordance with this aspect of the present invention in substantially the same manner as described

above with regard to treatment of demyelinated axons with oligodendrocyte progenitor cells.

In one embodiment of the present invention, oligodendrocyte progenitor cells are administered to the subject after administering radiation and before demyelination has occurred. The purpose of radiation administration is to treat primary and metastatic tumors of the central nervous system.

The subject treated with oligodendrocyte progenitor cells in accordance with the present invention is preferably a human and, most preferably, an adult or post-natal human.

A further aspect of the present invention relates to an *in vitro* method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This method involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. The oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

The step of removing neurons and neuronal progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types can be carried out by promoter based cell sorting. This procedure includes providing a mixed population of cell types from the brain and spinal cord which population includes neurons and neuronal progenitor cells as well as oligodendrocyte progenitor cells and selecting a promoter which functions in the neurons and neuronal progenitor cells, but not in the oligodendrocyte progenitor cells. A nucleic acid molecule encoding a marker protein under control of the promoter is introduced into the mixed population of cell types, and the population of neurons or neuronal progenitor cells is allowed to express the marker protein. The cells expressing the marker protein are separated from the mixed population of cells, with the separated cells being the neurons and neuronal progenitor cells. The process of selecting neurons and neuronal progenitor cells from a mixed population of cell types using a promoter that functions in the neurons and neuronal progenitor cells and a nucleic acid encoding a marker protein is described in U.S. Patent No. 6,245,564 to Goldman et. al., which is hereby incorporated by reference in its entirety.

The neurons and neuronal progenitor cells can be separated from a mixed population containing other mammalian brain or spinal cord cell types in accordance with the present invention, as long as a promoter specific for the chosen cell is available. "Specific", as used herein to describe a promoter, means that the promoter functions only in the chosen cell type. A chosen cell type can refer to different types of cells or different stages in the developmental cycle of a progenitor cell. For example, the chosen cell may be committed to a particular adult cell phenotype and the chosen promoter only functions in that progenitor cell; i.e. the promoter does not function in adult cells. Although committed and uncommitted progenitor cells may both be considered progenitor cells, these cells are at different stages of progenitor cell development and can be separated according to the present invention if the chosen promoter is specific to the particular stage of the progenitor cell. Those of ordinary skill in the art can readily determine a cell of interest to select based on the availability of a promoter specific for that cell of interest.

Suitable promoters which are specific for neurons or neuronal progenitor cells include a MAP-1B promoter (Liu and Fischer, Gene 171:307-308 (1996), which is hereby incorporated by reference in its entirety), an NCAM promoter (Holst et al., J Biol Chem 269:22245-22252 (1994), which is hereby incorporated by reference in its entirety), an HES-5 HLH protein promoter (Takebayashi et al., J Biol Chem 270:1342-1349 (1995), which is hereby incorporated by reference in its entirety), an α 1-tubulin promoter (Gloster, A., et al., J Neurosci 14:7319-7330 (1994), which is hereby incorporated by reference in its entirety), an α -internexin promoter (Ching et al., J Biol Chem 266:19459-19468 (1991), which is hereby incorporated by reference in its entirety), and a GAP-43 promoter (Starr et al., Brain Res 638:211-220 (1994), which is hereby incorporated by reference in its entirety).

Having determined the promoter specific for the neurons and neuronal progenitor cells, a nucleic acid molecule encoding a protein marker, preferably a green fluorescent protein, under the control of the promoter is introduced into a plurality of cells to be sorted.

The isolated nucleic acid molecule encoding a green fluorescent protein can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA, including messenger RNA or mRNA), genomic or recombinant, biologically isolated or synthetic. The DNA

- 11 -

molecule can be a cDNA molecule, which is a DNA copy of a messenger RNA (mRNA) encoding the GFP. In one embodiment, the GFP can be from *Aequorea victoria* (U.S. Patent No. 5,491,084 to Prasher et. al., which is hereby incorporated by reference in its entirety). A plasmid designated pGFP10.1 has been deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession No. 75547 on September 1, 1993. This plasmid is commercially available from the ATCC due to the issuance of U.S. Patent No. 5,491,084 on February 13, 1996 in which the plasmid is described. This plasmid comprises a cDNA which encodes a green fluorescent protein (GFP) of *Aequorea victoria* as disclosed in U.S. Patent No. 5,491,084 to Chalfie et al., which is hereby incorporated by reference in its entirety. A mutated form of this GFP (a red-shifted mutant form) designated pRSGFP-C1 is commercially available from Clontech Laboratories, Inc. (Palo Alto, California).

The plasmid designated pT α 1-RSGFP has been deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession No. 98298 on January 21, 1997. This plasmid uses the red shifted GFP (RS-GFP) of Clontech Laboratories, Inc. (Palo Alto, California), and the T α 1 promoter sequence provided by Dr. F. Miller (Montreal Neurological Institute, McGill University, Montreal, Canada). In accordance with the subject invention, the T α 1 promoter can be replaced with another specific promoter, and the RS-GFP gene can be replaced with another form of GFP, by using standard restriction enzymes and ligation procedures.

Mutated forms of GFP that emit more strongly than the native protein, as well as forms of GFP amenable to stable translation in higher vertebrates, are now available and can be used for the same purpose. The plasmid designated pT α 1-GFP_h has been deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, with the American Type Culture Collection

(ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession No. 98299 on January 21, 1997. This plasmid uses the humanized GFP (GFP_h) of Zolotukhin and Muzyczka (Levy, J., et al., Nature Biotechnol 14:610-614 (1996), which is hereby incorporated by reference in its entirety), and the Tα1 promoter sequence provided by Dr. F. Miller (Montreal). In accordance with the subject invention, the Tα1 promoter can be replaced with another specific promoter, and the GFP_h gene can be replaced with another form of GFP, by using standard restriction enzymes and ligation procedures. Any nucleic acid molecule encoding a fluorescent form of GFP can be used in accordance with the subject invention.

Standard techniques are then used to place the nucleic acid molecule encoding GFP under the control of the chosen cell specific promoter. Generally, this involves the use of restriction enzymes and ligation.

The resulting construct, which comprises the nucleic acid molecule encoding the GFP under the control of the selected promoter (itself a nucleic acid molecule) (with other suitable regulatory elements if desired), is then introduced into a plurality of cells which are to be sorted. Techniques for introducing the nucleic acid molecules of the construct into the plurality of cells may involve the use of expression vectors which comprise the nucleic acid molecules. These expression vectors (such as plasmids and viruses) can then be used to introduce the nucleic acid molecules into the plurality of cells.

Various methods are known in the art for introducing nucleic acid molecules into host cells. These include: 1) microinjection, in which DNA is injected directly into the nucleus of cells through fine glass needles; 2) dextran incubation, in which DNA is incubated with an inert carbohydrate polymer (dextran) to which a positively charged chemical group (DEAE, for diethylaminoethyl) has been coupled (the DNA sticks to the DEAE-dextran via its negatively charged phosphate groups, large DNA-containing particles stick in turn to the surfaces of cells (which are thought to take them in by a process known as endocytosis), and some of the DNA evades destruction in the cytoplasm of the cell and escapes to the nucleus, where it can be transcribed into RNA like any other gene in the cell); 3) calcium phosphate coprecipitation, in which cells efficiently take in DNA in the form of a precipitate with calcium phosphate; 4) electroporation, in which cells are placed in a solution

containing DNA and subjected to a brief electrical pulse that causes holes to open transiently in their membranes so that DNA enters through the holes directly into the cytoplasm, bypassing the endocytotic vesicles through which they pass in the DEAE-dextran and calcium phosphate procedures (passage through these vesicles may sometimes destroy or damage DNA); 5) liposomal mediated transformation, in which DNA is incorporated into artificial lipid vesicles, liposomes, which fuse with the cell membrane, delivering their contents directly into the cytoplasm; 6) biolistic transformation, in which DNA is absorbed to the surface of gold particles and fired into cells under high pressure using a ballistic device; 7) naked DNA insertion; and 8) viral-mediated transformation, in which nucleic acid molecules are introduced into cells using viral vectors. Since viral growth depends on the ability to get the viral genome into cells, viruses have devised efficient methods for doing so. These viruses include retroviruses, lentivirus, adenovirus, herpesvirus, and adeno-associated virus.

As indicated, some of these methods of transforming a cell require the use of an intermediate plasmid vector. U.S. Patent No. 4,237,224 to Cohen and Boyer, which is hereby incorporated by reference in its entirety, describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and replicated in unicellular cultures including procaryotic organisms and eucaryotic cells grown in tissue culture. The DNA sequences are cloned into the plasmid vector using standard cloning procedures known in the art, as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989), which is hereby incorporated by reference in its entirety.

In accordance with one of the above-described methods, the nucleic acid molecule encoding the GFP is thus introduced into a plurality of cells. The promoter which controls expression of the GFP, however, only functions in the cell of interest. Therefore, the GFP is only expressed in the cell of interest. Since GFP is a fluorescent protein, the cells of interest can therefore be identified from among the plurality of cells by the fluorescence of the GFP.

Any suitable means of detecting the fluorescent cells can be used. The cells may be identified using epifluorescence optics, and can be physically picked up

and brought together by Laser Tweezers (Cell Robotics Inc., Albuquerque, New Mexico). They can be separated in bulk through fluorescence activated cell sorting, a method that effectively separates the fluorescent cells from the non-fluorescent cells.

One embodiment of separating oligodendrocyte progenitor cells from the treated mixed population, in accordance with this aspect of the present invention, is carried out by promoter based cell separation as described above, except that rather than starting with the introduction of a nucleic acid molecule encoding a fluorescent protein under control of the promoter into the entire mixed population containing mammalian brain or spinal cord cell types besides the oligodendrocyte progenitor cells, that nucleic acid molecule is introduced into the treated mixed population. In sorting out oligodendrocyte progenitor cells from the treated mixed population, a promoter specific for oligodendrocyte progenitor cells is utilized. The promoter suitable for carrying out this aspect of the present invention can be a cyclic nucleotide phosphorylase I promoter, a myelin basic protein promoter, a JC virus minimal core promoter, a proteolipid protein promoter, a qk1 promoter (i.e. the promoter for the quaking gene product), and a cyclic nucleotide phosphorylase II promoter.

As an alternative to using promoter-based cell sorting to recover oligodendrocyte progenitor cells from the treated mixed population, an immunoseparation procedure is utilized.

This involves separating cells based on proteinaceous surface markers naturally present on progenitor cells of a specific type. For example, the surface marker A2B5 is an initially expressed early oligodendrocyte marker. See Nunes et al., "Identification and Isolation of Multipotential Neural Progenitor Cells from the Adult Human White Matter," Soc. Neurosci. Abstr. (2001), which is hereby incorporated by reference. Using an antibody specific to that marker oligodendrocyte progenitor cells can be separated from a mixed population of cell types. Such antibodies can be labeled with a fluorescent tag to facilitate separation of cells to which they bind. Alternatively, the antibodies can be attached to paramagnetic beads so that cells which bind to the beads through the attached antibodies can be recovered by a biomagnetic separation process.

A hybridoma producing monoclonal antibodies specific to Gq ganglioside, designated A2B5 has been deposited pursuant to, and in satisfaction of,

- 15 -

the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852 under ATCC Accession No. CRL-01520.

5 The enriched population of oligodendrocyte progenitor cells is at least 90% pure, preferably at least 95% pure, and most preferably at least 99% pure. The mixed population of cell types used to carry out this aspect of the present invention are preferably human cells. These cells are desirably adult or post-natal human cells.

 Instead of utilizing the above-described procedure of obtaining
10 oligodendrocyte progenitor cells by removing neurons and neuronal progenitor cells from a mixed population of brain and spinal cord cell types, leaving a treated mixed population and then separating the oligodendrocyte progenitor cells from the treated population, the oligodendrocyte progenitor cells can be recovered directly from the mixed population of brain and spinal cord cell types using promoter based cell sorting
15 as described in U.S. Patent No. 6,245,564 to Goldman, et. al., and U.S. Patent Application Serial No. 09/282,239 to Goldman et. al., which are hereby incorporated by reference in their entirety. This method is essentially as described above, using a promoter which functions only in oligodendrocyte progenitor cells.

EXAMPLES

Example 1 - Cells

- 5 Cells Tissue from late gestational age human fetuses (21 to 23 weeks) were obtained at abortion. The forebrain ventricular/subventricular zones were rapidly dissected free of the remaining brain parenchyma, and the samples chilled on ice. The minced samples were then dissociated using papain/DNAse as previously described (Keyoung et al., "Specific Identification, Selection and Extraction of Neural Stem
- 10 Cells from the Fetal Human Brain," Nature Biotechnology 19:843-850 (2001), which is hereby incorporated by reference in its entirety), always within 3 hours of extraction. The dissociates were then maintained overnight in minimal culture media of DMEM/F12/N1 with 20 ng/ml FGF.

Example 2 - Sorting

- 15 The day after dissociation, the cells were incubated 1:1 with MA6 A2B5 supernatant (clone 105; ATCC, Manassas, VA), for 30 minutes, then washed and labeled with microbead-tagged rat anti-mouse IgM (Miltenyi Biotech). All incubations were done at 4°C on a rocker. In some instances, 2-channel
- 20 fluorescence-activated cell sorting was done to define the proportions and phenotypic homogeneity of A2B5 and PSA-NCAM-defined subpopulations, using a FACS Vantage SE/Turbo, according to previously described methods (Keyoung et al., "Specific Identification, Selection and Extraction of Neural Stem Cells from the Fetal Human Brain," Nature Biotechnology 19:843-850 (2001) and Roy et al., "In Vitro
- 25 Neurogenesis by Progenitor Cells Isolated from the Adult Human Hippocampus," Nat Med 6:271-277 (2000), which are hereby incorporated by reference in their entirety). More typically, and for all preparative sorts for transplant purposes, magnetic separation of A2B5⁺ cells (MACS; Miltenyi) was next performed, following the manufacturer's protocol. The bound cells were then eluted and incubated with anti-
- 30 NCAM (PharMingen) at 1:25 for 30 minutes, and labeled with anti-mouse PE at 1:200. The PSA-NCAM⁺ population was then removed by FACS, leaving a highly

